全文获取类型
收费全文 | 268篇 |
免费 | 18篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 8篇 |
妇产科学 | 9篇 |
基础医学 | 32篇 |
口腔科学 | 8篇 |
临床医学 | 22篇 |
内科学 | 66篇 |
皮肤病学 | 4篇 |
神经病学 | 5篇 |
特种医学 | 48篇 |
外科学 | 16篇 |
综合类 | 6篇 |
预防医学 | 6篇 |
眼科学 | 2篇 |
药学 | 38篇 |
中国医学 | 1篇 |
肿瘤学 | 24篇 |
出版年
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 4篇 |
2013年 | 5篇 |
2012年 | 5篇 |
2011年 | 3篇 |
2010年 | 7篇 |
2009年 | 5篇 |
2008年 | 3篇 |
2007年 | 8篇 |
2006年 | 9篇 |
2005年 | 5篇 |
2004年 | 2篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 9篇 |
2000年 | 9篇 |
1999年 | 4篇 |
1998年 | 11篇 |
1997年 | 12篇 |
1996年 | 10篇 |
1995年 | 7篇 |
1994年 | 13篇 |
1993年 | 15篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 6篇 |
1989年 | 9篇 |
1988年 | 7篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1970年 | 2篇 |
1965年 | 1篇 |
排序方式: 共有297条查询结果,搜索用时 15 毫秒
1.
Hilde Tobi Paul B. van den Berg Lolkje TW de Jong‐van den Berg 《Pharmacoepidemiology and drug safety》2006,15(3):211-211
The original article to which this Erratum refers was published in Pharmacoepidemiology and Drug Safety 2005; 14: 239–247. 相似文献
2.
3.
Periosteal Ewing sarcoma 总被引:3,自引:0,他引:3
4.
Mervyn Israel Trevor W. Sweatman Ramakrishnan Seshadri Yoshihiro Koseki 《Cancer chemotherapy and pharmacology》1989,25(3):177-183
Summary
N-Benzyladriamycin-14-valerate (AD 198) is a new lipophilic adriamycin (ADR) analogue that shows marked therapeutic superiority to ADR in murine tumor model systems yet differs mechanistically from ADR in a number of ways. Among its other properties, AD 198 produces a delayed but profound effect on cell-cycle progression and a pattern of continuing DNA damage in cultured cells briefly exposed to the drug. Using radiolabeled drug forms and radioassays combined with HPLC separation and fluorimetric detection techniques, aspects of drug accumulation, biotransformation, and retention in cultured human CEM leukemic lymphocytes were studied, in part to determine a possible pharmacologic basis for the latent effects seen with this drug. In addition, the cellular pharmacology of AD 198 and ADR were comparatively examined under identical experimental conditions. When CEM cells were incubated with drug at equi-growth inhibitory/minimally cytotoxic concentrations (AD 198, 1.0 M; ADR, 0.1 M), a number of differences were apparent. Under conditions of continuous 24-h drug exposure, a slow cellular accumulation and equilibration was observed with ADR (cell: medium equilibrium, 1:11 after 4–6 h), whereas the uptake of AD 198 was rapid and extensive (cell: medium equilibrium, 3:1 within 30 min). In drug-retention studies, when cells were pretreated at the same drug concentrations as before (AD 198 for 1 h; ADR for 4 h) and then transferred to drug-free media, both compounds re-equilibrated their intracellular drug content with the fresh media, losing about 50% of their respective anthracycline levels. Liquid chromatographic analysis of ADR-treated cultures under both sets of conditions showed the parent drug to be the only intracellular anthracycline species, whereas analysis of AD 198-treated cultures revealed two fluorescent signals corresponding to the parent drug and its 14-deesterified biotransformation product,N-benzyladriamycin (AD 288). Levels of AD 288 rose from 2% of the total intracellular anthracycline content immediately on drug admixture to 61% following 24 h continuous drug exposure and to 69% at 24 h in cells exposed to drug for 1 h and then continued in drug-free media for 24 h. At all times, the balance of the intracellular anthracycline fluorescence was attributable to the parent drug; no ADR was detectable in AD 198-treated cells by either fluorescence detection or radioassay. Thus, AD 198 is not a prodrug form of ADR, and the in vitro effects of this agent, including the latent effects on cell-cycle inhibition and DNA damage seen in cells following short-term drug exposure, can be explained on the basis of the high levels of active parent drug and biotransformation product that accumulate and persist in the cells.Abbreviations ADR
adriamycin (doxorubicin)
- AD 198
N-benzyladriamycin-14-valerate
- AD 288
N-benzyladriamycin
- AD 32
N-trifluoroacetyladriamycin-14-valerate
- AD 143
N-trifluoroacetyladriamycin-14-0-hemiadipate
- AD 41
N-trifluoroacetyladriamycin
- [14C]-AD 198
[benzyl]--methylene-14C]-N-benzyladriamycin-14-valerate
- [14C]-ADR
[14-14C]-adriamycin
- HPLC
high-performance liquid chromatography
- TLC
thin-layer chromatography
- DMSO
dimethylsulfoxide
- S-MEM
Eagle's minimum essential medium for suspension culture
- PBS
phosphate-buffered saline (pH 7.0) 相似文献
5.
Protriptyline in obstructive sleep apnea: a double-blind trial 总被引:6,自引:0,他引:6
L G Brownell P West P Sweatman J C Acres M H Kryger 《The New England journal of medicine》1982,307(17):1037-1042
We evaluated protriptyline, a nonsedating tricyclic antidepressant, as a treatment for obstructive sleep apnea in a double-blind crossover study of five men. After two weeks of treatment, with no change in body weight, daytime somnolence was markedly reduced and nocturnal oxygenation was improved, although apnea duration and frequency were not significantly decreased. Rapid-eye-movement (REM) stage time as a fraction of the total sleep time was reduced during treatment from 0.231 +/- 0.031 to 0.107 +/- 0.013 (mean +/- S.E.M.) (P less than 0.05). REM apnea time as a fraction of total sleep time was reduced from 0.145 +/- 0.022 to 0.054 +/- 0.006 (P less than 0.05). REM reduction during treatment with protriptyline can account for decreased REM apnea time. Similar decreases in REM stage time and REM apnea duration and similar improvement in oxygenation continued after six months of treatment. In addition, body weight, apnea, and arousal frequency were decreased at this time. Although the obstructive sleep apnea was not resolved, it was reduced. Protriptyline can be effective in patients with sleep apnea when the disorder is not life-threatening. 相似文献
6.
Lovering Ruth; Middleton-Price Helen R.; O'Reilly Marie-Anne J.; Genet Sally A.; Parkar Mohammed; Sweatman Angela K.; Bradley Linda D.; Alterman Lesley A.; Malcolm Sue; Morgan Gareth; Levinsky Roland J.; Kinnon Christine 《Human molecular genetics》1993,2(2):139-141
Genetic linkage analysis has been instrumental in mapping thegene for X-linked agammaglobulinemia (XLA) to the proximal longarm of the human X chromosome, to Xq22. Due to the relativerarity of this disease the localization of the gene within Xq22has remained imprecise. We have investigated twenty-nine familiesaffected by XLA and have found no recombinants with the DXS178locus in over 30 informative meioses. DXS178 is now the mostreliable and informative locus for use in pre-natal diagnosisand carrier detection of XLA. In addition, we have identifiednew closely linked proximal and distal flanking markers forXLA, DXS442 and DXS101, respectively. These loci are separatedby 2cM, considerably reducing the extent of DNA within whichthe XLA locus can be contained. This will open up the way formore directed positional cloning efforts for the isolation ofthe XLA gene. 相似文献
7.
A new restriction fragment length polymorphism at the DXS101 locus allows carrier detection in a family with X linked agammaglobulinaemia.
下载免费PDF全文
![点击此处可从《Journal of medical genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A Sweatman R Lovering H Middleton-Price A Jones G Morgan R Levinsky C Kinnon 《Journal of medical genetics》1993,30(6):512-514
The gene responsible for X linked agammaglobulinaemia (XLA) lies in Xq22 and has recently been identified as atk. DXS101 is a polymorphic locus which is closely linked to the disease locus. In this report we describe the identification, by pulsed field gel electrophoresis, of a new polymorphism at the DXS101 locus with a predicted heterozygosity of 4.9%. Despite this low value, we show how this polymorphism has been important in carrier status determination in a family with XLA where assessment was not possible by other means. 相似文献
8.
Michael L. Jones Julie Gassaway W. Mark Sweatman 《The journal of spinal cord medicine》2021,44(3):383
ObjectiveEvaluate effectiveness of peer interventions on self-efficacy, unplanned hospital readmissions, and quality of life for patients with spinal cord injury (SCI) undergoing inpatient rehabilitation.DesignInterrupted time-series analysis (ITSA) examined effects of peer interventions on unplanned readmissions. Intervention variables added to ITSA regression examined relationships with exposure to peer interventions. Heterogeneity of treatment effects (HTE) analysis examined differences in intervention effectiveness for patients with quadriplegia and paraplegia.SettingRehabilitation hospital specializing in SCI and brain injury.ParticipantsSCI inpatients (n = 1117) admitted for rehabilitation whose discharge location was home (77% male, 71% Caucasian, mean age 38.2 (SD 16.8)). A subsample of 799 patients participated in secondary analyses examining relationship between peer interventions, readmissions, changes in patient-reported outcomes, and HTE.InterventionsOne-to-one mentoring and participation in peer-led self-management classes.Main outcome measuresUnplanned readmissions, general self-efficacy (GSE), and depressive symptoms 30, 90, and 180 days post discharge; satisfaction with life at 180 days.ResultsAfter implementing the peer interventions, we observed a significant decrease in both level and slope of number of patients readmitted, and level only of unplanned hospital days 30-days post-discharge. Reduction in the number of patients and unplanned hospital days was associated with number of peer visits but not peer-led education classes attended. Higher self-efficacy (GSE) was associated with greater exposure to peer mentoring, and a significant relationship between improvement in GSE and reduced hospital readmissions was observed.ConclusionsOne-to-one peer mentoring improves self-efficacy and reduces unplanned hospital readmissions following inpatient rehabilitation for persons with SCI. 相似文献
9.
Metabolism and elimination of rhodamine 123 in the rat 总被引:1,自引:0,他引:1
Trevor W. Sweatman Ramakrishnan Seshadri Mervyn Israel 《Cancer chemotherapy and pharmacology》1990,27(3):205-210
Summary Little is known of the pharmacology of rhodamine 123 (RH-123), an agent reported to have carcinoma-selective experimental antitumor activity. Accordingly, using a high-performance liquid chromatographic assay system with fluorescence detection, we examined the plasma decay and the biliary and urinary elimination of parent drug and metabolites in female Sprague-Dawley rats receiving RH-123 at an intravenous dose (5 mg/kg) equivalent to the therapeutic dose used in murine tumor models. Following drug administration to unconscious animals, plasma levels of drug-associated fluorescence fell in a triphasic manner (t1/2, 15 min; t1/2, 1 h; t1/2, 4.7 h). In plasma, unchanged drug predominated but lower levels of the deacylated metabolite rhodamine 110 (RH-110) and two unknowns were also detectable throughout the study. Drug fluorescence was recovered extensively in both urine and bile. In unconscious animals with ureteral cannulae, urinary excretion (11.4% of the dose in 6 h) occurred predominantly as unchanged RH-123 (97% of the total), with low levels of RH-110 (2.4%) and two unknowns (<0.6% combined) also being present. Similarly dosed conscious animals (without surgical intervention) housed in metabolic cages showed a comparable pattern of urinary excretion, with 11.9% of the drug dose being recovered in 6 h and 21.9%, by 48 h. Biliary drug elimination accounted for 8% of the delivered dose in 6 h in unconscious animals and for 11% by 36 h in conscious animals fitted with biliary cannulae. In contrast to urinary excretion, in which unchanged drug predominated, only 50% of the fluorescence recovered in bile was attributable to RH-123. The remainder was due to a number of products that were detectable throughout the study. Of these, one present at significant levels was identified as a glucuronide conjugate of RH-123, based on the liberation of parent drug when the purified metabolite was incubated with -glucuronidase or hydrolyzed with 1 N hydrochloric acid. Further studies with a radiolabeled form of RH-123 are necessary to establish the identity of the remaining unknowns disclosed in this work.This work was supported in part by research grants CA 44890 (T.W.S.) and CA 37082 (M.I.) from the National Cancer Institute, National Institutes of Health, United States Public Health Service 相似文献
10.
同种异体黑素细胞移植治疗白癜风 总被引:2,自引:2,他引:0
0 引言 白癜风患者免疫紊乱 ,黑素细胞 (melanocyte,MC)异体移植有可能不被排斥 ,治疗如成功将有很大临床前景 [1 ] .探索同种异体黑素细胞移植后的效果很有意义 .1 病例报告 女 ,2 7岁 ,确诊白癜风 (稳定期 ) ,患者皮肤自幼出现色素脱失斑 ,逐渐增多扩大 . 1996年外用“敏白灵”,前2 mo有效 . 1999- 0 7外用补骨酯酊 ,日服 5 g· L- 1 硫酸铜 10m L和中药 1剂 ,转移因子 4m L ,sc,1· 2 d- 1 .皮损缩小 ,4mo后稳定 .用健康男青年环切的包皮培养 MC,第 4代大约80 %融合时 ,用 2 .5 g· L- 1 胰酶消化 5 min,加入含 2 0 0 g·L- 1小… 相似文献